Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03978611
Title A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | ESP | DEU | CAN | BEL


No variant requirements are available.